Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Light fuse and stand well back - because this is taking off in 2024
and the sky is the only limitation
RBC target is 60p (will outperform the market)
imho dyo
Chief Executive Carolyn Cross says: "We have put great efforts into improving our commercial activity sales process, which has increased the speed of the average sales cycle from contact to deployment by 50%. We have appointed distributors in the UK, Spain, and Mexico and are gaining real momentum. What is particularly encouraging is that many hospitals are recommending Steriwave to other hospitals. We believe this momentum will continue to increase, and commercial sales will become more significant in 2024."
Am in total agreement with Rocket
Ondine met its 2023 target and more than doubled the number of hospitals using its groundbreaking photodisinfection technology to reduce healthcare-associated infections (HAIs)
· According to the NIH, HAIs affect more than 2 million patients a year in the US, leading to over 90,000 deaths and incurring costs exceeding $30 billion a year.[1]
Following its successful fundraising of C$4.91 million (US$3.62), Canadian life sciences company Ondine Biomedical Inc. (AIM: OBI) will continue accelerating commercialisation of its proven nasal photodisinfection technology. This cutting-edge technology replaces topical antibiotics for the prevention of healthcare-associated infections (HAIs) and kills all types of pathogens - bacteria, viruses and fungi - without causing antimicrobial resistance.
The Company has confirmed that it has more than doubled the number of Steriwave® deployments in 2023 and is in discussions with more than 75 hospitals in the UK, Mexico, Spain, and Canada. The growing global emphasis on preventing HAIs post-surgery, coupled with the escalating challenge of antimicrobial resistance, has spurred heightened interest in Ondine's photodisinfection technology.
The deployments are in areas of major surgery, including spinal, orthopedic, and cardiovascular. The antibiotic mupirocin has been used for nasal decolonization for the prevention of HAIs since the 1980s. However, mupirocin has resistance rates of up to 81%,[2] and very poor compliance.[3]
Successful C$4.91 raise supports ongoing commercialisation
Pentwater employs a bottom-up, opportunistic investment approach with a focus on event driven investing across the capital structure. Active risk management and capital preservation are key priorities. The seasoned Pentwater team enjoys a collaborative culture across the firm’s offices and strategies. In addition to our investment process, we are committed to providing investors with institutional quality client service, operations, and compliance.
Notification of major holdings
Ondine Biomedical Inc - Vancouver-based life sciences company - Says it has raised GBP2.9 million via a placing. Says it will issue a further 1.1 million new shares at 9 pence each, representing a 9% premium to the closing price at November 29. Says it will use the proceeds to support its commercialisation in Canada, the UK, Spain and Mexico, and will provide a cash runway until at least the middle of the second quarter in 2024.
Https://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=obi.L
9.65-10.29
waiting on exciting new results
Analyst says 60p target
inho dyor
Ondine Biomedical Inc - Vancouver-based life sciences company - Raises GBP2.5 million via placing and subscription. Further, in light of the demand for the placing and subscription, increases overall fundraising size from GBP2.5 million cap as commitments already received mean that there are insufficient shares to allocate to the broker option or to employee subscribers.
Expect 15p very soon
imho - dyor
RBC says overperform with target 60p
Currently 9.35-9.95p
It is all up from here
imho - dyor
We are pleased to have the support of existing and new investors through this fundraising which meets our near-term working capital needs and assists our rapid commercial growth rate. This funding will take us forward commercially and further our discussions with industry partners on our clinical, financial, and global distribution objectives.
We believe that our product, Steriwave, is very well positioned to help hospitals meet their infection control objectives, reduce their antibiotic usage and combat AMR in what will be a multibillion-dollar market. Our commercial efforts are benefitting both from the growing support for pre-surgical nasal decolonisation by leading organisations, as well as our real-world clinical successes in Canadian hospitals over the last 10 years.
While we are currently focused on nasal decolonisation to prevent healthcare-associated infections, we have a pipeline of products in various stages of development using the same platform technology. These platform products target the treatment of burns, wounds, chronic sinusitis, ventilator-associated pneumonia, and fungal infections and will leverage our regulatory filings and the clinical successes related to our nasal decolonisation product."
The only way is up
imho - dyor
8.36-8.68
Great time to buy cause it wont stay down for long
imho - dyor
The results of the study showed that treatment with photodisinfection resulted in >99.9% reduction of viable bacteria compared to the control, regardless of the antibiotic susceptibility of the bacteria. The authors concluded that photodisinfection is likely an important adjunct to AMR strategies in the future and that further clinical studies are warranted.
Antimicrobial resistance (AMR) remains a major public health concern, causing 33,000 deaths in Europe annually( 1 (#_edn1) ) which is projected to rise to over 10 million globally by 2050.( 2 (#_edn2) ) There are widespread multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections across the world which are mainly caused by Gram-negative bacteria including Enterobacteriaceae and P. aeruginosa AMR bacteria( 3 (#_edn3) )(,( 4 (#_edn4) )) and Gram-positive bacteria such as Staphylococcus spp.( 5 (#_edn5) ) Steriwave has been found to be highly effective against all these pathogens.
Photodisinfection uses a photosensitizer and a specific wavelength of light to trigger photochemical reactions that produce reactive oxygen species. These reactive oxygen species are lethal to a broad spectrum of microbes, including bacteria, fungi, and viruses. Importantly, photodisinfection does not induce antimicrobial resistance formation.